- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04034303
Risk Factors for the Development of Celiac Disease in Genetically Predisposed Children (NEOCEL)
Natural History, Risk Factors and Predictive Biomarkers for Celiac Disease: a Prospective Multicenter Study.
Study Overview
Status
Intervention / Treatment
Detailed Description
- CD epidemics: Celiac Disease incidence is increasing at unexpected rates in the last two decades in all gluten-consuming populations.
- Remarkable stratified genetic risk: there is a strong genetic component as the main risk to develop disease, as supported by > 85% concordance in monozygotic twins, but genetics cannot change over decades and does not explain the epidemic which has been observed. The presence of double HLA DQ2 in female subjects does increases the risk of disease above that of a mendelian recessive inheritance. Hence the estimation of environmental factors associated to the genetic risk is quite complex and does need a very strict prospective longitudinal study design, since each factor is likely to produce, if ever, a quite small odds ratio .
- Gene expression in the first year of life: we have observed, in our previous cohort studies, that the expression of at least a small set of CD associated candidate genes is substantially different between the children who eventually develop Cd and those who do not, already a 6 months of age, much before any measurable recognition of the gluten antigen, development of antibodies or any clinical sign (ref 3 Galatola).
- Epigenetic changes in small intestinal tissue: in addition of the previously reported gene expression differences, gene methylation and related expression of CD associated candidate genes have been observed in the epithelium and the lamina propria of Cd patients . In addition, microRNA appear to be differently expressed in patients versus controls.
- Early events in the first-second year of life before diagnosis: our groups and others observed that the occurrenceof acute respiratoryinfections in the first and second year of life, at least 12 months before the onset of disease, was associated to increased odds (> x2) of developing CD. It is most likely that viral infections (as the large majority of URTI in children) play a role in the development of food antigen intolerance leading to CD . A role of non-pathogenic viral infections has been also suggestedin the developmentof intolerance to gluten.
- No influence of breast-feeding or gluten introduction: breast feeding does not prevent the incidence of CD in at risk infants: its most likely effect is to delay the onset of clinical symptoms. Similarly, the time and quantity of gluten introduction is not associated to the actual incidence, but is only associated to delayed time effects.
- Possible implication of microbiome: despite the complexity of estimating differences in the composition of microbiome in the infants, it has been suggested that infants who later develop CD might show a fila composition slightly different from their matched controls.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Campania
-
Naples, Campania, Italy, 80131
- University of Naples Azienda Ospedaliera Universitaria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Pregnant women from a family with a confirmed CD proband
Exclusion Criteria:
Women affected by severe chronic disease and cancer Women not able to attend the schedule of visits
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Celiac Disease
Time Frame: 6 years
|
Number of new cases of infants affected by Celiac Disease in relation to genetic (HLA and non-HLA Associated Genes), Epigenetic (DNA Methylation, Gene Expression, Istone Acetylation of candidate gene) and environmental factors (Maternal factors, Nutrition, Infections)
|
6 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of microbiome
Time Frame: 6 years
|
Difference in the microbiome composition of the group of infants who eventually develop Celiac Disease versus those who do not develop the disease. Comparison of Fecal Microbiome of infants at 4, 12 and 24 months subgrouped by outcome. |
6 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEOCEL2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Clinical Symptoms in Celiac Disease
-
The University of Texas Health Science Center,...CompletedUnderstanding of Consent in Clinical Research | Implementation of Consent in Clinical ResearchUnited States
-
waleed mohammad sabryRecruitingthe Clinical Effect of Surgical Tube Technique in Reconstruction of the Interproximal PapillaEgypt
-
Azienda Ospedaliera di LeccoUnknownDefinition of Sample Size in Randomized Clinical Trial Assessing Liver DiseaseItaly
-
Tampere University HospitalActive, not recruitingPrevention of In-hospital Adverse EventsFinland
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
-
Schneider Children's Medical Center, IsraelUnknownCeliac Disease in ChildrenIsrael
-
Tampere University HospitalTurku University Hospital; Kuopio University Hospital; Seinajoki Central Hospital and other collaboratorsEnrolling by invitationCeliac Disease | Diet, Gluten-Free | Celiac Disease in Children | Follow-up | Transition of CareFinland
-
ASST Fatebenefratelli SaccoNot yet recruiting
Clinical Trials on analysis of genetic and epigenetic risk factors
-
Medical Research CouncilUnknownEsophageal Cancer | Precancerous ConditionUnited Kingdom
-
Centre Leon BerardCentre de Recherche en Cancérologie de LyonCompletedBreast Cancer | MetastasisFrance
-
Leeds Cancer Centre at St. James's University HospitalUnknownMelanoma (Skin) | Hereditary Multiple MelanomaUnited Kingdom
-
Stanford UniversityCompleted
-
IRCCS Policlinico S. DonatoRecruitingMarfan Syndrome | Marfan's Syndrome With Cardiovascular ManifestationsItaly
-
Cancer Research Centre at Weston Park HospitalUnknown
-
Boston Medical CenterBoston University; Eunice Kennedy Shriver National Institute of Child Health... and other collaboratorsRecruitingPregnancy, High Risk | Alcohol Use Disorder | Opioid-use Disorder | Neonatal Abstinence SyndromeUnited States
-
Interleukin Genetics, Inc.Duke University; Kaiser PermanenteWithdrawnPERIODONTAL DISEASE
-
Portland VA Medical CenterCompletedProstate Cancer | Hereditary Prostate CancerUnited States
-
Hospices Civils de LyonRecruitingColorectal Cancer | Ovarian Cancer | Secondary Peritoneal CancersFrance